Atherosclerosis licenses for an exceeding immune response in COVID-19 disease by interferon priming in circulating myeloid cells
Cardiovascular Research · 2026
DOI: 10.1093/cvr/cvaf268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2026. Verfasst von Julian Leberzammer und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cardiology, Goethe University Hospital, Frankfurt, Germany. Hauptthemen laut MEDLINE: COVID-19, Atherosclerosis, Myeloid Cells, Interferon Type I. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: German Research Foundation, German Center for Cardiovascular Research, Amandus and Barbara Pauli Foundation.
Abstract (Originalsprache)
Aims
Patients with cardiovascular disease (CVD) have an increased risk of developing severe respiratory infections, including COVID-19. However, the underlying molecular mechanisms are not completely understood. It has been previously shown that CVD predisposes to an altered responsiveness to subsequent inflammatory triggers by an imprinted epigenetic memory in innate immune cells. Therefore, we hypothesized that patients with pre-existing atherosclerotic cardiovascular disease (ASCVD) and COVID-19 display a dysregulated inflammatory response compared to patients without ASCVD due to epigenetically altered immune cells leading to increased disease severity. Methods and results Single-cell RNA sequencing revealed a dysregulated myeloid immune response with hyperinflammatory and immunosuppressive features in patients with ASCVD and moderate COVID-19. Assay for Transposase-Accessible Chromatin sequencing and in vitro experiments with isolated monocytes infected with SARS-CoV-2 showed epigenetic priming of monocytes from patients with ASCVD towards increased expression of inflammatory mediators and type I interferon signalling. In a German nationwide cohort (NAPKON), using multiplex cytokine assays, enzyme-linked immunosorbent assays, and bulk-RNA sequencing, we confirmed that patients with ASCVD display an exaggerated inflammatory response during moderate COVID-19.
Conclusion
This study demonstrates that patients with ASCVD show a dysregulated myeloid immune response in moderate COVID-19 disease. Mechanistically, epigenetic imprinting sensitizes myeloid cells of patients with ASCVD to an exaggerated type I interferon-associated immune response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Cardiology, Goethe University Hospital, Frankfurt, Germany.
- Institute of Cardiovascular Regeneration, Goethe University, Frankfurt, Germany.
- German Center for Cardiovascular Research, Berlin (partner site Rhine-Main), Germany.
- Cardiopulmonary Institute (CPI), Frankfurt 60590, Germany.
- Institute for Medical Virology, Goethe University, Frankfurt, Germany.
- Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
ORCID-Profile: Julian Leberzammer, David John, Stefan Günther, Mario Looso, Vladimir Benes, Christoph Stellbrink, Christoph Römmele, Andreas M Zeiher, Stefanie Dimmeler, Sebastian Cremer
Förderung
- German Research Foundation
- German Center for Cardiovascular Research
- Amandus and Barbara Pauli Foundation
- Heinrich and Fritz Riese Foundation
- German Heart Foundation
- Network of University Medicine
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Leberzammer, J., Abplanalp, W. T., Grikscheit, K., Solomonidis, E. G., Glaser, S. F., Schuhmacher, B., Merten, M., Jeremijev, G., Wilken-Schmitz, A., Korth, L., John, D., Günther, S., Kuenne, C., Looso, M., Valasarajan, C., Benes, V., Jung, F., Niehaus, V., Anton, G., …, & Cremer, S. (2026). Atherosclerosis licenses for an exceeding immune response in COVID-19 disease by interferon priming in circulating myeloid cells. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf268
Vancouver
Leberzammer J, Abplanalp WT, Grikscheit K, Solomonidis EG, Glaser SF, Schuhmacher B, et al. Atherosclerosis licenses for an exceeding immune response in COVID-19 disease by interferon priming in circulating myeloid cells. Cardiovascular Research. 2026. doi:10.1093/cvr/cvaf268
BibTeX
@article{Leberzammer2026,
author = {Leberzammer, Julian and Abplanalp, Wesley Tyler and Grikscheit, Katharina and Solomonidis, Emmanouil G and Glaser, Simone-Franziska and Schuhmacher, Bianca and Merten, Maximilian and Jeremijev, Gligorije and Wilken-Schmitz, Annett and Korth, Lara and John, David and Günther, Stefan and Kuenne, Carsten and Looso, Mario and Valasarajan, Chanil and Benes, Vladimir and Jung, Ferris and Niehaus, Vivianne and Anton, Gabriele and Stellbrink, Christoph and Römmele, Christoph and Göpel, Siri and Pullamsetti, Soni Savai and Vehreschild, Janne and Vehreschild, Maria and Ciesek, Sandra and Leistner, David M and Zeiher, Andreas M and Dimmeler, Stefanie and Cremer, Sebastian},
title = {Atherosclerosis licenses for an exceeding immune response in COVID-19 disease by interferon priming in circulating myeloid cells},
journal = {Cardiovascular Research},
year = {2026},
doi = {10.1093/cvr/cvaf268}
}
EUVIMED